| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SERPINA4 |
| Uniprot No | P29622 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-427aa |
| 氨基酸序列 | QLHVEHDGES CSNSSHQQIL ETGEGSPSLK IAPANADFAF RFYYLIASET PGKNIFFSPL SISAAYAMLS LGACSHSRSQ ILEGLGFNLT ELSESDVHRG FQHLLHTLNL PGHGLETRVG SALFLSHNLK FLAKFLNDTM AVYEAKLFHT NFYDTVGTIQ LINDHVKKET RGKIVDLVSE LKKDVLMVLV NYIYFKALWE KPFISSRTTP KDFYVDENTT VRVPMMLQDQ EHHWYLHDRY LPCSVLRMDY KGDATVFFIL PNQGKMREIE EVLTPEMLMR WNNLLRKRNF YKKLELHLPK FSISGSYVLD QILPRLGFTD LFSKWADLSG ITKQQKLEAS KSFHKATLDV DEAGTEAAAA TSFAIKFFSA QTNRHILRFN RPFLVVIFST STQSVLFLGK VVDPTKP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SERPINA4重组蛋白的3篇参考文献的简要概括(基于模拟生成，非真实文献)：
---
1. **文献名称**：*Recombinant SERPINA4 inhibits vascular inflammation through antagonizing TNF-α-induced endothelial activation*
**作者**：Zhang Y, et al.
**摘要**：本研究通过大肠杆菌系统表达重组SERPINA4蛋白，发现其能显著抑制TNF-α诱导的内皮细胞炎症因子(如IL-6、VCAM-1)表达，并减轻小鼠动脉粥样硬化模型中的斑块形成，提示其在血管疾病中的治疗潜力。
2. **文献名称**：*Structural and functional characterization of recombinant human SERPINA4/kallistatin*
**作者**：Chen L, et al.
**摘要**：利用X射线晶体学解析了重组人SERPINA4蛋白的三维结构，揭示了其与激肽释放酶的结合位点。功能实验表明，重组蛋白可通过阻断激肽介导的信号通路抑制肿瘤细胞迁移，为癌症治疗提供新靶点。
3. **文献名称**：*SERPINA4 recombinant protein attenuates liver fibrosis via modulating TGF-β/Smad signaling*
**作者**：Wang H, et al.
**摘要**：在肝星状细胞和小鼠肝纤维化模型中，重组SERPINA4通过抑制TGF-β/Smad通路减少胶原沉积，改善肝功能指标，表明其作为抗纤维化药物的潜在价值。
---
注：以上内容为模拟创作，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of SERPINA4 Recombinant Protein**
SERPINA4. also known as kallistatin, belongs to the serine protease inhibitor (SERPIN) superfamily, which regulates proteolytic enzymes critical for diverse physiological processes. This glycoprotein is primarily synthesized in the liver and circulates in plasma, functioning as a potent inhibitor of tissue kallikrein, an enzyme involved in blood pressure regulation, inflammation, and vascular remodeling. Structurally, SERPINA4 contains a reactive center loop (RCL) that interacts with target proteases, forming a stable complex to block their activity.
Recombinant SERPINA4 is produced using biotechnological platforms (e.g., mammalian or bacterial expression systems) to ensure high purity and bioactivity. Its production enables detailed study of molecular mechanisms, including anti-inflammatory, antioxidant, and anti-angiogenic properties. Research highlights its dual role in pathophysiology: while it protects against vascular dysfunction and organ damage in conditions like hypertension and diabetes, it may also exhibit context-dependent pro-inflammatory effects in certain cancers.
Therapeutic exploration focuses on SERPINA4's potential in treating cardiovascular diseases, septic shock, and fibrotic disorders. Recombinant variants are also utilized as tools in immunoassays, protein interaction studies, and drug screening. Recent studies emphasize its interplay with nitric oxide signaling and heparin-binding domains, expanding its relevance in cellular homeostasis. Despite progress, challenges remain in understanding tissue-specific regulation and post-translational modifications. SERPINA4 recombinant protein thus serves as a vital reagent for dissecting protease-inhibitor networks and developing targeted therapies.
×
